ANAB

AnaptysBio Inc.

Price

$59.26

return (12m)

349.17%

p/e

-61.92

p/bv

130.10

DIVIDEND YIELD

0.00%

ANAB price

AnaptysBio

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ANAB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

15.57%

3 months

-1.90%

1 year

349.17%

2 years

143.87%

5 years

266.86%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ANAB

Valuation

P/E

-61.92

Sector -4.38

Industry -4.38

P/BV

130.10

Sector 2.02

Industry 2.02

P/Revenue (PSR)

7.14

Sector -4.40

Industry -4.40

EV/EBITDA

-43.73

Sector -263.09

Industry -263.09

EV/EBIT

-42.90

Sector -702.90

Industry -702.90

P/EBITDA

28.36

Sector -4.39

Industry -4.39

P/EBIT

29.59

Sector -4.73

Industry -4.73

P/Total Assets

5.03

Sector 1.49

Industry 1.49

P/Net Current Assets

-1,998.55

Sector -11.70

Industry -11.70

P/Working Capital

6.04

Sector -3.19

Industry -3.19

EPS

-0.92

Sector -2.14

Industry -2.14

BVPS

0.44

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-122.77%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-125.16%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

17.55%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-11.53%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.08

Sector 0.03

Industry 0.03

Profitability

ROE

-210.12%

Sector -65.14%

Industry -65.14%

ROA

-8.13%

Sector -65.53%

Industry -65.53%

ROIC

-570.77%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

7.58

Sector 2.90

Industry 2.90

Net Debt / EBITDA

9.13

Sector -6.07

Industry -6.07

Net Debt / EBIT

8.95

Sector -8.26

Industry -8.26

Net Debt / Equity

-22.47

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.04

Sector 0.41

Industry 0.41

Liabilities/Assets

0.96

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

29.76%

Sector -

Industry -

5Y Earnings CAGR

-14.25%

Sector -

Industry -

Fundamentals ANAB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ANAB AnaptysBio Inc.	$59.26	349.17%	0.00%	-61.92	130.10	-210.12%	-11.53%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ANAB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT AnaptysBio

AnaptysBio Inc.

Average Investor10 user rating

4.0 (1 people)

United States

21 years

Founded: 2005

2017

Time since IPO - 9 years

94

Employees

AnaptysBio Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.66 billion, with shareholders equity totaling $12.75 million.

The company employs approximately 94 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, AnaptysBio Inc. reported $232.39 million in revenue, generating net income of $-26.79 million.

Key financial metrics include a P/E ratio of -61.92, a price-to-book (P/B) ratio of 130.10, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ANAB.

Market cap

$1.66 billion

Net worth

$12.75 million

$12,750,000.00

Assets

$329.68 million

$329,680,000.00

Total Shares Outstanding

29.00 million

29,000,000

Average Daily Trading Volume

$632.40 Thousand

$632,404.00

Sector

Health Care

Industry

Biotechnology

ANAB

ANAB revenue and profits

Financial Results ANAB

DRAG THE FRAME TO SEE MORE DATA

ANAB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of AnaptysBio (ANAB) today?

A cotação de AnaptysBio (ANAB) hoje está em US$ 59.26, com uma variação de 349.17% em relação ao último ano. A cotação de AnaptysBio (ANAB) iniciou o ano negociando na casa dos US$ 48.48 e hoje está em US$ 59.26. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de AnaptysBio (ANAB) e dados de ações do Ibovespa e mercados internacionais.

Quando AnaptysBio (ANAB) paga dividendos?

AnaptysBio (ANAB) não distribuiu dividendos no último ano.

Is AnaptysBio (ANAB) a good investment?

Atualmente, AnaptysBio (ANAB) está cotada a US$ 59.26, com um P/L de -61.92, representando um desvio de -2,772% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 349.17 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 349.17%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy AnaptysBio (ANAB) stock?

Investir em ações de AnaptysBio (ANAB) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of AnaptysBio (ANAB) yield today?

A rentabilidade de AnaptysBio (ANAB) foi de 15.57% no último mês, 349.17% no último ano e 266.86% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de AnaptysBio (ANAB) hoje, o investimento total seria de US$ 5,926.00, com base na cotação atual de US$ 59.26.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 26,617.81
Em 5 anos: US$ 21,740.12
Em 10 anos: US$ 5,926.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ANAB

AnaptysBio Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ANAB

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING ANAB WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT AnaptysBio

AnaptysBio Inc.

United States

21 years

2017

94

PROFIT X PRICE ANAB

Financial Results ANAB

ANAB cash flow

Asset, Revenue and Profit Growth - ANAB

ANAB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions